The purpose of this study is to:
- Provide raltegravir to subjects with HIV and an undetectable viral load who are
experiencing injection site reactions (ISR) to Enfuvirtide,
- Monitor the safety and efficacy of raltegravir, and
- Assess the change in quality of life in patients who have switched from Enfuvirtide to
raltegravir